Bladder Cancer Weekly

July 13, 2026

Videos

Peer-to-Peer Clinical Conversations

Neoadjuvant Chemoimmunotherapy with Intravesical rBCG in Muscle-Invasive Bladder Cancer - Richard Cathomas

Richard Cathomas

Richard Cathomas presents a phase 2 trial combining neoadjuvant atezolizumab, cisplatin/gemcitabine, and intravesical recombinant BCG followed by radical cystectomy.

View

Pelvic Floor Disorders and Sexual Dysfunction in Female Bladder Cancer Survivors - Raveen Syan

Raveen Syan

Raveen Syan presents data on pelvic floor disorders in female bladder cancer patients.

View

Beyond the Abstracts

Real-World Effectiveness of Avelumab, Pembrolizumab, and Enfortumab Vedotin in Patients with Advanced Urothelial Carcinoma with Squamous Differentiation (ARON-2EV) - Beyond the Abstract

Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists - Beyond the Abstract

Conference Coverage

ASCO 2026: UTOPIA: A Phase 3 Trial of UGN-103, an Intravesical Mitomycin Reverse Thermal Hydrogel, in Recurrent Low Grade Intermediate Risk NMIBC

ASCO 2026: HRQoL with Neoadjuvant and Adjuvant EV + Pembro in Patients with MIBC Who Are Cisplatin-Ineligible: Phase 3 KEYNOTE-905 Study

AUA 2026: Costs of Care and Oncologic Outcomes Associated with Blue Light Cystoscopy in an Equal Access Setting: Results from the BRAVO Study

AUA 2026: Evaluating Effect of Prior Checkpoint Inhibitor Exposure on Disease Control with Enfortumab Vedotin + Pembrolizumab in First Line Metastatic Bladder Cancer

EAU 2026: Factors Associated with Inferior Outcomes in Patients with Advanced Urothelial Carcinoma Treated with First-Line Enfortumab Vedotin + Pembrolizumab: Results from UNITE

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Comparative effectiveness of intravesical gemcitabine vs. sequential gemcitabine and docetaxel for high-risk nonmuscle-invasive bladder cancer.

Proteomic analysis of sphingolipid metabolic enzymes with risk of bladder cancer incidence and mortality in the Atherosclerosis Risk in Communities (ARIC) Study.

Impact of body mass index on outcomes after radical cystectomy: A retrospective Australian cohort study.

Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-making.

MRI-based Response Assessment of Neoadjuvant Systemic Immunotherapy in Muscle-invasive Bladder Cancer: An Analysis of Inter-radiologist Variability and Diagnostic Accuracy in three Prospective Clinical Trials.

The impact of cachexia and sarcopenia in bladder cancer.

Diagnosis, Evaluation, and Management of Patients with Non-Muscle Invasive Bladder Cancer - Beyond the Abstract

Beyond the bladder: case series of Mycobacterium bovis bacillus Calmette-Guérin infections following intravesical instillation.

Phase I first-in-human dose-escalation trial of a bladder cancer-specific nanoparticle in non-muscle-invasive bladder cancer.

The Impact of Relative Dose Intensity on pCR in Neoadjuvant Chemotherapy of Muscle-Invasive Urothelial Cancer: a Multicentre Retrospective Study.

Outcomes of Consolidative Surgery Following Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Cancer: A Real-World Experience - Beyond the Abstract

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Durable Responses and Cystectomy Avoidance with IL-15 Receptor Agonist NAI plus BCG In BCG-Unresponsive NMIBC with Carcinoma In Situ +/- Papillary Disease.

Outcomes of maintenance BCG versus gemcitabine/docetaxel following BCG induction in NMIBC.

Proliferation- and cytotoxic immune signatures identify chemotherapy-responsive bladder tumors in a molecular subtype dependent manner.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Bladder Cancer Weekly

Bladder Cancer

Login